Detection of compound mode of action by computational integration of whole-genome measurements and genetic perturbations

BACKGROUND: A key problem of drug development is to decide which compounds to evaluate further in expensive clinical trials (Phase I- III). This decision is primarily based on the primary targets and mechanisms of action of the chemical compounds under consideration. Whole-genome expression measurem...

Descripción completa

Detalles Bibliográficos
Autores principales: Hallén, Kristofer, Björkegren, Johan, Tegnér, Jesper
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1403807/
https://www.ncbi.nlm.nih.gov/pubmed/16451737
http://dx.doi.org/10.1186/1471-2105-7-51

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1403807/
https://www.ncbi.nlm.nih.gov/pubmed/16451737
http://dx.doi.org/10.1186/1471-2105-7-51

Ejemplares similares